Crysvita Reaches One-Month-Old Infants in the EU, and Buys Two More Years of Orphan Exclusivity
- The European Commission approved expanding Crysvita (burosumab) to infants from 1 month to 1 year of age with X-linked hypophosphataemia, across the EU and EEA.
- The decision follows the CHMP positive opinion in April 2026 and is supported by BUR-CL207 (NCT04188964), a Phase 1/2 open-label multicentre study in paediatric patients from birth to one year.
- XLH is a rare, progressive genetic disease of phosphate wasting driven by excess FGF23, impairing bone mineralisation and causing skeletal deformity, impaired growth, bone pain and hearing loss. Burosumab is an antibody that blocks FGF23.
- The approval also extends Crysvita’s EU orphan market exclusivity by two years, from February 2028 to February 2030.
Access read
Read the exclusivity line, not the indication line. A paediatric extension in an ultra-rare disease is one of the most dependable lifecycle plays available, and this one is unusually clean because both cases are genuine at once. Clinically, XLH damages the skeleton from the first months of life, so starting at one month rather than twelve is a real change in outcome rather than a label technicality. Commercially, the same approval pushes EU orphan protection out to 2030 on a franchise that was facing a 2028 cliff. Those two things rarely align this neatly, and for anyone modelling rare-disease franchises the lesson is where the value hides: the infant indication is not a rounding error, it is the exclusivity.